IPO Databook: Immvira Bioscience (HK) - Jul 2026

111 Views18 Jul 2026 10:06

SUMMARY

Immvira Bioscience Inc. is a clinical-stage biotechnology company focused on novel oncolytic immunotherapies and engineered exosome therapies, aiming to be a global leader in bladder cancer treatment.
Immvira, incorporated in 2015, has a pipeline of two oncolytic immunotherapy candidates and five engineered exosome assets. MVR-T3011 received FDA Fast Track Designation for HNSCC in March 2024.
The company reported a loss of RMB(518,861) for 2025, with net current liabilities of RMB(2,390,634) as of May 31, 2026.

This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream